These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6773281)

  • 1. Cytogenetic analysis of an immunogenic mutant of the L5178Y lymphoma.
    Greenberg AH; Manougian J; Ray M; Goldenberg GJ
    Acta Cytol; 1980; 24(3):232-6. PubMed ID: 6773281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic shifts in the L5178Y lymphoma population during progression of the tumor-dormant state in DBA/2 mice.
    Trainer DL; Wheelock EF
    Cancer Res; 1984 Mar; 44(3):1063-71. PubMed ID: 6607108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel tumor-specific antigen(s) response observed in a syngeneic lymphoma-bearing host.
    Manson LA
    Cancer Detect Prev Suppl; 1987; 1():111-20. PubMed ID: 3121177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of L5178Y cell phenotypes isolated during progression of the tumor-dormant state in DBA2 mice.
    Trainer DL; Wheelock EF
    Cancer Res; 1984 Jul; 44(7):2897-906. PubMed ID: 6609767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase of L5178Y lymphoma growth by means of placental antigen immunization.
    Bravo-Cuéllar A; Gomez-Estrada H; Ramos-Damián M
    Arch Invest Med (Mex); 1982; 13(3):191-4 passim. PubMed ID: 7125799
    [No Abstract]   [Full Text] [Related]  

  • 7. Increase of growth of the L5178Y murine lymphoma by means of immunization with radiated L5178Y cells.
    Ramos-Damián M; Gómez-Estrada H; Acosta-Ruiz R; Díaz-Esquivel P; Vázquez-Escobosa C
    Arch Invest Med (Mex); 1982; 13(1):29-31. PubMed ID: 7065806
    [No Abstract]   [Full Text] [Related]  

  • 8. Elimination of L5178Y cells from tumor-dormant DBA/2 mice by specific active immunotherapy.
    Marsili MA; Robinson MK; Truitt GA; Wheelock EF
    Cancer Res; 1983 Jan; 43(1):15-21. PubMed ID: 6600159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-resolution cytogenetic characterization of the L5178Y TK+/- mouse lymphoma cell line.
    Sawyer JR; Moore MM; Hozier JC
    Mutat Res; 1989 Oct; 214(2):181-93. PubMed ID: 2797024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic properties of lymphoma sublines derived from a drug-treated immunogenic L5178Y leukemia.
    Fioretti MC; Romani L; Taramelli D; Goldin A
    Transplantation; 1978 Dec; 26(6):449-51. PubMed ID: 734739
    [No Abstract]   [Full Text] [Related]  

  • 11. Location of tumoral antigens in L5178Y murine lymphoma cells.
    Ramos-Damián ME; Gómez-Estrada H; Hernández-Delgado J; Tapia-Arizmendi L; Feria-Velasco A
    Arch Invest Med (Mex); 1980; 11(3):425-34. PubMed ID: 7469659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic analysis of the L5178Y/TK+/- leads to TK-/- mouse lymphoma mutagenesis assay system.
    Hozier J; Sawyer J; Moore M; Howard B; Clive D
    Mutat Res; 1981 Nov; 84(1):169-81. PubMed ID: 7329431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors.
    Dye ES; North RJ
    J Leukoc Biol; 1984 Jul; 36(1):27-37. PubMed ID: 6234371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alanine inhibits cytotoxic responses: its production by different tumor cell lines explains differences in their immunogenicity.
    Dröge W; Wehrmaker A; Eck HP
    Cancer Detect Prev; 1988; 11(3-6):151-6. PubMed ID: 3134127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo lysis of L5178Y cells in the establishment of the tumor-dormant state in DBA/2 mice.
    Wheelock EF; Weinhold KJ; Ingenito GG; Goldstein LT
    J Immunol; 1980 Apr; 124(4):1642-7. PubMed ID: 7365237
    [No Abstract]   [Full Text] [Related]  

  • 16. Dacarbazine-induced immunogenicity of a murine leukemia is attenuated in cells transfected with mutated K-ras gene.
    Testorelli C; Bussini S; De Filippi R; Marelli O; Orlando L; Greiner JW; Grohmann U; Tentori L; Giuliani A; Bonmassar E; Graziani G
    J Exp Clin Cancer Res; 1997 Mar; 16(1):15-22. PubMed ID: 9148855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells.
    von Hoegen P; Altevogt P; Schirrmacher V
    Cell Immunol; 1987 Oct; 109(2):338-48. PubMed ID: 3117377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable dicentric chromosomes induced by chemical mutagens in L5178Y mouse lymphoma cells.
    Blazak WF; Stewart BE; Galperin I; Allen KL; Rudd CJ; Mitchell AD; Caspary WJ
    Mutat Res; 1986 Apr; 173(4):263-6. PubMed ID: 3951473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined chemoimmunotherapy of L5178Y lymphoma.
    Balázová E; Koza I; Ujházy V
    Neoplasma; 1978; 25(6):653-7. PubMed ID: 752113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine tumor.
    Grohmann U; Puccetti P; Belladonna ML; Fallarino F; Bianchi R; Binaglia L; Sagakuchi K; Mage MG; Appella E; Fioretti MC
    J Immunol; 1995 May; 154(9):4630-41. PubMed ID: 7722315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.